Congress Demands Answers on Data Privacy Ahead of 23andMe Sale

As the popular genetic testing company 23andMe prepares for a potential sale, Congress is stepping in to demand answers on data privacy concerns.

Lawmakers are seeking transparency on how 23andMe plans to protect the genetic information of its customers in the event of a sale.

Concerns have been raised about the potential misuse of sensitive genetic data, which could have far-reaching implications for individuals’ privacy and security.

Congress is also looking into how 23andMe collects, stores, and shares genetic information, and whether proper safeguards are in place to prevent unauthorized access.

The company’s sale could have significant implications for the future of data privacy in the genetic testing industry, prompting lawmakers to take action.

23andMe has faced criticism in the past for its handling of customer data, leading to calls for greater oversight and regulation of the industry.

With the potential sale on the horizon, Congress is urging 23andMe to provide clear answers on how it intends to protect the privacy of its customers moving forward.

Lawmakers are also considering potential legislation to address data privacy issues in the genetic testing industry, in order to ensure that individuals’ sensitive information is adequately protected.

As the debate over data privacy and genetic testing continues to evolve, Congress is committed to holding companies like 23andMe accountable for safeguarding the privacy and security of their customers’ genetic information.